Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12067113 | 1.00 | SPHK2 (0.42) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL6683104 | 0.94 | TERT (0.43) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL2116370 | 0.88 | S1PR1 (0.45) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL25681705 | 0.87 | — | — | |
| SCHEMBL23828670 | 0.87 | S1PR1 (0.41) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL23645217 | 0.84 | S1PR1 (0.49) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL24577734 | 0.84 | S1PR1 (0.49) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL3431942 | 0.83 | SPHK2 (0.47) | SPHK2SPHK1TERTHTTHRH3 | |
| SCHEMBL3427098 | 0.83 | SPHK2 (0.47) | SPHK2SPHK1TERTHTTHRH3 | |
| SCHEMBL3429567 | 0.83 | SPHK2 (0.47) | SPHK2SPHK1TERTHTTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | SPHK2 1493/4885SPHK1 2201/4885S1PR1 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.